Equities research analysts expect Flexion Therapeutics, Inc. (NASDAQ:FLXN) to announce sales of $24.61 million for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Flexion Therapeutics’ earnings, with the lowest sales estimate coming in at $24.60 million and the highest estimate coming in at $24.63 million. Flexion Therapeutics reported sales of $20.13 million during the same quarter last year, which indicates a positive year over year growth rate of 22.3%. The firm is scheduled to report its next quarterly earnings results on Thursday, May 6th.
On average, analysts expect that Flexion Therapeutics will report full year sales of $123.90 million for the current year, with estimates ranging from $120.60 million to $130.80 million. For the next year, analysts forecast that the firm will post sales of $192.43 million, with estimates ranging from $175.00 million to $223.50 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Flexion Therapeutics.
Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings data on Tuesday, March 9th. The specialty pharmaceutical company reported ($0.37) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.07. The firm had revenue of $26.31 million for the quarter, compared to analyst estimates of $26.60 million.
Shares of NASDAQ:FLXN traded up $0.12 on Wednesday, hitting $8.73. The stock had a trading volume of 1,819,134 shares, compared to its average volume of 838,465. The company has a market capitalization of $435.84 million, a price-to-earnings ratio of -2.83 and a beta of 1.64. The company has a debt-to-equity ratio of 12.77, a quick ratio of 4.31 and a current ratio of 4.66. The firm’s 50 day moving average price is $9.86 and its 200-day moving average price is $11.30. Flexion Therapeutics has a twelve month low of $7.80 and a twelve month high of $14.39.
In other news, insider Melissa Layman sold 2,624 shares of Flexion Therapeutics stock in a transaction dated Thursday, January 28th. The shares were sold at an average price of $12.55, for a total value of $32,931.20. Following the completion of the transaction, the insider now owns 91,000 shares of the company’s stock, valued at approximately $1,142,050. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 17.03% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the business. Eaton Vance Management boosted its stake in shares of Flexion Therapeutics by 73.3% during the 4th quarter. Eaton Vance Management now owns 30,500 shares of the specialty pharmaceutical company’s stock worth $352,000 after acquiring an additional 12,900 shares during the period. Phocas Financial Corp. acquired a new stake in Flexion Therapeutics during the fourth quarter worth approximately $2,661,000. Hsbc Holdings PLC bought a new stake in shares of Flexion Therapeutics during the fourth quarter worth approximately $151,000. Virtu Financial LLC acquired a new position in shares of Flexion Therapeutics in the fourth quarter valued at approximately $117,000. Finally, Fort Pitt Capital Group LLC bought a new position in shares of Flexion Therapeutics during the fourth quarter worth approximately $46,000.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.